Antiviral treatment in patients with concurrent infection of hepatitis C and hepatitis B

WANG Haiyan; DENG Qun

doi:10.3969/j.issn.1002-7386.2016.22.004

Abstract：Objective To investigate the clinical characteristics in patients with concurrent infection of hepatitis C and hepatitis B,and to observe the antiviral curative effects of pegylated interferon (PEGIFNα-2a) combined with ribavirin on the disease.Methods A total of 132 patients who were treated in our hospital from January 2013 to December 2015 were enrolled in the study.These patients were divided into three groups, in which 45 patients with concurrent infection of hepatitis C and hepatitis B in group A,49 patients with simple HBV infection in group B,and 38 patients with simple HCV infection in group C.The infectious status of pateints and the antiviral curative effects were observed and compared among the three groups.Results There were significant differences in HBeAg positive rate, HBV DNA positive rate, average value of HBV DNA and the distribution of patients with HBV DNA between group A and group B ( P <0.05).There was no significant difference in average value of HCV RNA between group A and group C ( P >0.05 ) , however, there was a significant difference in the distribution of patients with HBV DNA bewteen group A and group C ( P <0.05) .There were no significant differences in the distribution of genotype,HCV RNA,ALT between group A and group C ( P >0.05),however, there were significant differences in PLT, WBC, PTA,Alb between the two groups ( P <0.05).InⅠgenotype, there were significant differences in pEVR,ETVR and relapse rate between group A and group C ( P >0.05),but there were no significant differences in RVR,cEVR and SVR between the two groups ( P >0.05).Moreover in non-Ⅰgenotype, there were no significant differences in RVR, cEVR, pEVR, ETVR, SVR and relapse rate between the two groups ( P >0.05).There were significant differences in the cases with adverse reactions or the decrease of WBC, PLT between group A and group C (P<0.05), however, there were no significant differences in the cases with haemolysis or hypothyrosis between the two groups ( P >0.05).Besides there was a significant difference in positive conversion rate between the patients with SVR and patients without SVR ( P <0.05).Conclusion HCV is dominant in patients with concurrent infection of HCV and HBV, and HBV replication is suppressed.The relapse rate, partial early virological response and the virological response at end of treatment in patients with concurrent infection ofⅠgenotype are higher than those in patients with simple HCV infection, moreover, sustained virological response is similar,however, concurrent infection has no effects on virological response in non-Ⅰgenotype.